Search

Guido Me Lanza

from San Francisco, CA
Age ~48
Get Report
Also known as:
Guido M Lanza, Guido E Lanza, Me Lanza Guido, Lanza Guido, Us Guido
Phone and address:
359 Green St, San Francisco, CA 94133
(415) 398-4393
Related to:
Mary Shea, 83Randolph Ruiz, 53Michael J Sulpizio, 47Bryan J Sulpizio, 50Mary Lee, 80
Connected to:
Ada D Lanza, 75Carlos A Lanza, 62Cheryl J Lanza, 68Christina R Lanza, 48David J Lanza, 63Edesio C Lanza, 65Edgar Lanza, 36Erick D Lanza, 27Harold G Lanza, 74Isabel Lanza, 68

Guido Lanza Phones & Addresses

  • 359 Green St, San Francisco, CA 94133 (415) 398-4393
  • San Gabriel, CA
  • Stateline, NV
  • 108 Esplanade Ave, Pacifica, CA 94044 (650) 359-7659
  • Palo Alto, CA

Work

Company: Numerate Mar 2007 Position: Chief executive officer

Education

Degree: Master of Science, Masters School / High School: The University of Manchester 1998 to 1999 Specialities: Bioinformatics

Industries

Biotechnology

Resumes

Resumes

Guido Lanza Photo 1

Vice President Of Innovation

View page
Location:
San Francisco, CA
Industry:
Biotechnology
Work:
Numerate
Chief Executive Officer
Pharmix Jan 2001 - Feb 2007
Chief Technology Officer
Genetic Programming Jan 2000 - Dec 2000
Research Scientist
Valo Jan 2000 - Dec 2000
Vice President of Innovation
Education:
The University of Manchester 1998 - 1999
Master of Science, Masters, Bioinformatics University of California, Berkeley 1994 - 1998
Bachelors, Bachelor of Arts, Genetics

Business Records

Name / Title
Company / Classification
Phones & Addresses
Guido Lanza
President And Chief Executive Officer
Numerate, Inc.
Noncommercial Research Organizations
1150 Bayhill Dr Ste 203, San Bruno, CA 94066
Guido Lanza
President, President And Chief Executive Officer
Numerate, Inc.
Biotechnology · Noncommercial Research Organization
1150 Bayhill Dr SUITE 203, San Bruno, CA 94066
(650) 472-0632, (650) 396-7574
Guido M. Lanza
Lanza Techventures Management I, LLC
Venture Capital Investment
165 University Ave, Palo Alto, CA 94301
Guido Lanza
President And Chief Executive Officer
Numerate, Inc.
Noncommercial Research Organizations
1150 Bayhill Dr Ste 203, San Bruno, CA 94066

Publications

Wikipedia

Sahaja Yoga

View page

According to an official Sahaja Yoga website, Guido Lanza, a World Leader, was suspended from all activities in Sahaja Yoga in 2005, for disrupting a havan ...

Us Patents

Compositions And Treatments For Inhibiting Kinase And/Or Hmg-Coa Reductase

View page
US Patent:
7183285, Feb 27, 2007
Filed:
Apr 29, 2005
Appl. No.:
11/118066
Inventors:
John Griffin - Atherton CA, US
Guido Lanza - San Francisco CA, US
Jessen Yu - San Francisco CA, US
Assignee:
Pharmix Corp. - Brisbane CA
International Classification:
A01N 43/58
US Classification:
514256, 514247, 514183
Abstract:
The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.

Estimating The Accuracy Of Molecular Property Models And Predictions

View page
US Patent:
7194359, Mar 20, 2007
Filed:
Jun 29, 2005
Appl. No.:
11/172216
Inventors:
Nigel P. Duffy - San Francisco CA, US
Guido Lanza - San Francisco CA, US
Jessen Yu - San Francisco CA, US
Assignee:
Pharmix Corporation - Brisbane CA
International Classification:
G01N 1/30
US Classification:
702 27, 435 405
Abstract:
Embodiments of the invention provide methods for evaluating the accuracy of a molecular model properties model (or predictions generated using a molecular properties model). The accuracy of a molecular properties model may be evaluated using three general approaches, (i) by using the same data set to both train the model and to estimate the accuracy of the model, (ii) by using distinct data sets to train and subsequently test a model, and (iii) by using multiple models (or sets of predictions).

Compositions And Treatments For Inhibiting Kinase And/Or Hmg-Coa Reductase

View page
US Patent:
7199126, Apr 3, 2007
Filed:
Apr 29, 2005
Appl. No.:
11/118065
Inventors:
John Griffin - Atherton CA, US
Guido Lanza - San Francisco CA, US
Jessen Yu - San Francisco CA, US
Assignee:
Pharmix Corporation - Brisbane CA
International Classification:
A01N 43/54
US Classification:
514256, 514247, 514183
Abstract:
The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.

Modeling Biological Effects Of Molecules Using Molecular Property Models

View page
US Patent:
7856321, Dec 21, 2010
Filed:
Dec 14, 2005
Appl. No.:
11/304209
Inventors:
Guido Lanza - San Francisco CA, US
Nigel P. Duffy - San Francisco CA, US
Paul Boardman - South San Francisco CA, US
Assignee:
Numerate, Inc. - San Bruno CA
International Classification:
G01N 33/48
G06G 7/48
US Classification:
702 19, 703 11
Abstract:
Method, apparatus, and article of manufacture for modeling the biological effects of a molecule are disclosed. A machine learning application may be configured to process a set of training examples regarding a biological property of interest. Once trained, the machine learning application may be configured to generate a prediction regarding a property of interest for a test molecule. Embodiments of the invention provide a meta-model configured to generate a biological effect prediction for a molecule based on the predictions generated for the test molecule by a plurality of molecular property models.

Compositions And Treatments For Inhibiting Kinase And/Or Hmg-Coa Reductase

View page
US Patent:
20050272770, Dec 8, 2005
Filed:
Apr 29, 2005
Appl. No.:
11/118090
Inventors:
John Griffin - Atherton CA, US
William Mydlowec - San Francisco CA, US
Guido Lanza - San Francisco CA, US
Jessen Yu - San Francisco CA, US
International Classification:
A61K031/445
US Classification:
514317000, 514327000
Abstract:
The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.

Methods For Molecular Property Modeling Using Virtual Data

View page
US Patent:
20050278124, Dec 15, 2005
Filed:
Mar 8, 2005
Appl. No.:
11/074587
Inventors:
Nigel Duffy - San Francisco CA, US
Guido Lanza - San Francisco CA, US
Jessen Yu - San Francisco CA, US
William Mydlowec - San Francisco CA, US
International Classification:
G06F019/00
G01N033/48
G01N033/50
US Classification:
702019000, 702027000
Abstract:
Embodiments of the invention provide methods, systems, and articles of manufacture for modeling molecular properties based on information obtained from sources other than direct empirical measurements of the properties. Embodiments of the invention use “virtual data” related to molecular properties to train a molecular properties model. Virtual data about a molecule may include real-valued data (e.g. measurement values falling along a continuous range) or a positive or negative assertion about whether a molecule exhibits a property of interest. Virtual data may be generated using a variety of techniques and may be further characterized by confidence in the accuracy of the virtual data. In addition to virtual data, embodiments of the invention may use “virtual molecules” paired with “virtual data” to train a molecular properties model. The virtual molecules may themselves be generated in a variety of ways.

Compositions And Treatments For Inhibiting Kinase And/Or Hmg-Coa Reductase

View page
US Patent:
20050282883, Dec 22, 2005
Filed:
Apr 29, 2005
Appl. No.:
11/118113
Inventors:
John Griffin - Atherton CA, US
Guido Lanza - San Francisco CA, US
Jessen Yu - San Francisco CA, US
International Classification:
A61K031/405
A61K031/4025
A61K031/401
US Classification:
514420000, 514460000, 514422000, 514423000, 514548000
Abstract:
The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA-reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.

Compositions And Treatments For Inhibiting Kinase And/Or Hmg-Coa Reductase

View page
US Patent:
20050288306, Dec 29, 2005
Filed:
Apr 29, 2005
Appl. No.:
11/118064
Inventors:
John Griffin - Atherton CA, US
Guido Lanza - San Francisco CA, US
Jessen Yu - San Francisco CA, US
International Classification:
A61K031/506
A61K031/4439
A61K031/4178
US Classification:
514256000, 514341000, 514397000, 514406000
Abstract:
The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.
Control profile
Guido Me Lanza from San Francisco, CA, age ~48 Get Report